By modulating Ndufa4 expression to influence the metabolic profile and interferon responsiveness of differentiated colonocytes, miR147 emerges as a potential therapeutic target for both IBD and colorectal cancer. This evidence concerns the gene COXFA4 and colorectal cancer.